Association Between Cytomegalovirus and Epstein-Barr Virus Viremia And Human Immunodeficiency Virus DNA Levels in the Reservoir of Kenyan Infants Receiving Antiretroviral Therapy-Reference-Cited by-同舟云学术

Association Between Cytomegalovirus and Epstein-Barr Virus Viremia And Human Immunodeficiency Virus DNA Levels in the Reservoir of Kenyan Infants Receiving Antiretroviral Therapy

Published:2020-10-16 Issue:11 Volume:223 Page:1923-1927
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Slyker Jennifer A¹²,Guthrie Brandon¹²,Pankau Mark¹³,Tapia Kenneth¹,Wamalwa Dalton⁴,Benki-Nugent Sarah¹,Ngugi Evelyn⁵,Huang Meei-Li⁶,Njuguna Irene¹²,Langat Agnes⁵,John-Stewart Grace¹²⁷⁸,Lehman Dara¹³

Affiliation:

1. Department of Global Health, University of Washington, Seattle, Washington, USA

2. Department of Epidemiology, University of Washington, Seattle, Washington, USA

3. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

4. Department of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya

5. Centers for Disease Control and Prevention, CDC-Kenya, Nairobi, Kenya

6. Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA

7. Department of Medicine, University of Washington, Seattle, Washington, USA

8. Department of Pediatrics, University of Washington, Seattle, Washington, USA

Abstract

Abstract Identifying determinants of human immunodeficiency virus (HIV) reservoir levels may inform novel viral eradication strategies. Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) coinfections were assessed as predictors of HIV proviral DNA level in 26 HIV RNA–suppressed Kenyan children starting antiretroviral therapy before 7 months of age. Earlier acquisition of CMV and EBV and higher cumulative burden of systemic EBV DNA viremia were each associated with higher HIV DNA level in the reservoir after 24 months of antiretroviral therapy, independent of HIV RNA levels over time. These data suggest that delaying or containing CMV and EBV viremia may be novel strategies to limit HIV reservoir formation.

Funder

National Institutes of Health

National Institute of Allergy and Infectious Diseases

Eunice Kennedy Shriver National Institute of Child Health and Human Development

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiaa640/34400103/jiaa640.pdf

Reference15 articles.

1. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study;Sáez-Cirión;PLoS Pathog,2013